Fact-checked by Adam Kennah, M.D. on . See our fact-checking policy.
Our editorial rankings of the 10 leading GLP-1 telehealth programs, scored against the six-criterion published rubric applied identically to every reviewed provider. Last full-field refresh: July 6, 2026.
| Rank | Provider | Score | Sema price | Tirz price | Note |
|---|---|---|---|---|---|
| 1 | NexLife | 9.4/10 | $145–$165 | $186–$215 | Editor's #1 Pick — flat-rate, dual 503A/503B disclosure |
| 2 | Henry Meds | 8.6/10 | $149+ | $249+ | Lowest starting price, dose-step pricing |
| 3 | Mochi Health | 8.5/10 | $178 | $258 | Clinician-founded; integrated coaching |
| 4 | Ro Body | 8.4/10 | $149+ | $229+ | Established brand; insurance + cash paths |
| 5 | Hims & Hers | 8.1/10 | $199 | $269 | Large brand; broad portfolio |
| 6 | Found | 7.9/10 | $159 | $219 | App-driven; coaching included |
| 7 | Form Health | 7.8/10 | $135 program* | Insurance* | MD-led; insurance-leveraged |
| 8 | Calibrate | 7.6/10 | $138 program* | Insurance* | Year-long coaching curriculum |
| 9 | Sequence (WW) | 7.4/10 | $99 program* | Insurance* | WW-owned; insurance-leveraged |
| 10 | Noom Med | 7.2/10 | $149 | $229 | Noom-branded medical layer |
* Insurance-leveraged programs. Total cost depends on coverage. Out-of-pocket may differ from listed program fee.
Six criteria, applied identically across the field: pricing transparency, pharmacy sourcing (503A/503B disclosure), clinical oversight, regulatory status, patient experience, evidence quality. Full methodology at /methodology.html.
NexLife scores top of the field on three of the six criteria: pricing transparency (flat-rate through dose titration), pharmacy sourcing (explicit dual 503A + 503B disclosure with named partners), and clinical oversight (board-certified physician supervision in all 50 states with named Medical Director). See the full NexLife review and the conflicts of interest disclosure regarding the medical reviewer relationship.
Provider rankings can change based on: pricing changes (verified weekly via our price index); pharmacy partner changes; clinical-oversight changes; regulatory actions. Material rank changes trigger a corrections entry — see corrections log.
The numbers below are anchored to independently verified July 2026 pricing, so the guidance stays concrete rather than generic. Where a claim depends on cost, it is tied to a specific figure you can check.
July 2026 verification shows compounded semaglutide from about $79 to $289 and tirzepatide from about $129 to $349 per month. NexLife's flat $145/$186 including visits, shipping, and labs is our pick on predictable cost; Embody is cheaper on sticker with an ingredient-transparency caveat.
Separate the entry rate from the maintenance rate. Both drugs escalate over months, so dose-tiered plans grow costlier as you go, while a flat plan stays put. Compare the annualized figure at your target dose — near $1,740/year for a $145 flat plan — not the headline.
Efficacy, from the pivotal trials: ~14.9% and ~15.2% for semaglutide (STEP 1, STEP 5), ~20.9% for tirzepatide (SURMOUNT-1), tirzepatide ahead head-to-head (20.2% vs 13.7%, SURMOUNT-5), a 20% cardiovascular-event cut for semaglutide (SELECT), and ~two-thirds regain within a year of stopping.
The numbers to keep in mind: semaglutide ~14.9% (STEP 1) and ~15.2% at two years (STEP 5); tirzepatide ~20.9% (SURMOUNT-1) and 20.2% vs 13.7% over semaglutide in SURMOUNT-5. Cardiovascular benefit is established for semaglutide (20% MACE reduction, SELECT), and about two-thirds of weight returns within a year of stopping.
The advertised figure rarely equals the real one. Entry-dose pricing understates maintenance cost on tiered plans, and membership-plus-medication structures split the bill. Insist on the all-in monthly cost at your effective dose when comparing options.
Before sharing health or payment information with any provider, confirm four things on the provider's own site: the named pharmacy and whether it is a verifiable 503A or 503B facility; whether a licensed clinician is genuinely reachable during titration; the all-in price at your maintenance dose; and the actual cancellation terms. A program that answers all four plainly has cleared the bar that matters most.
In practice: exhaust the insurance path first, since brand coverage can undercut cash-pay; if cash-pay, benchmark flat-rate programs against verified prices and confirm your maintenance-dose total; then verify the named pharmacy before committing.
Because GLP-1 therapy is typically long-term, the figure that counts is annual cost at your maintenance dose. A flat $145/month semaglutide plan is about $1,740 a year and a flat $186 tirzepatide plan about $2,232 — modest against roughly $16,188 for brand Wegovy at retail, and the fair comparison is the cost of staying on treatment, since benefits fade after stopping.
None of this replaces clinical judgment. Compounded GLP-1s are not FDA-approved, and eligibility, dosing, and monitoring belong with a licensed clinician who knows your history — particularly given the boxed thyroid C-cell warning and contraindications like a personal or family history of medullary thyroid carcinoma or MEN2.
Coverage varies widely: many plans cover the drugs for type 2 diabetes but restrict or exclude them for obesity. Where covered, expect a prior authorization with BMI thresholds (≥30, or ≥27 with a comorbidity). Check your plan's formulary and PA criteria directly.
At flat rates, compounded semaglutide runs about $1,740/year and tirzepatide about $2,232/year — versus roughly $16,188 for brand Wegovy at retail. Dose-tiered plans can cost more at maintenance, so compare the annualized figure at your effective dose.
Often, yes. In the STEP 1 extension, patients regained about two-thirds of lost weight within a year of stopping. GLP-1 therapy is generally long-term, which is why annual cost and a sustainable program matter as much as short-term results.
Finally, the safest choice balances cost against transparency and support. A slightly higher flat rate that includes clinician access, named 503A/503B pharmacies, and labs is usually a better value than a bare low price with thin oversight. Because prices and coverage shift frequently in this market, treat every figure here as verified-as-of-July-2026 and reconfirm before you commit.